Characteristics of all 533 eligible patients and of 418 patients achieving CR or PR of at least 75% after induction CTx and randomized for consolidation treatment
| . | Eligible patients . | Patients randomized for consolidation treatment . | |||
|---|---|---|---|---|---|
| MOPP/ABV × 8 . | ABVPP × 8 . | MOPP/ABV × 6 + RTx . | ABVPP × 6 + RTx . | ||
| No. of patients | 533 | 92 | 116 | 114 | 96 |
| Male gender (%) | 66 | 73 | 68 | 68 | 67 |
| Age | |||||
| Median (y) | 32 | 32 | 32 | 32 | 32 |
| ≥45 y (%) | 23 | 21 | 16 | 17 | 22 |
| Stage | |||||
| IIIB (%) | 40 | 52 | 41 | 39 | 46 |
| IVA (%) | 12 | 10 | 11 | 13 | 10 |
| IVB (%) | 48 | 38 | 48 | 48 | 44 |
| Mediastinum (%) | |||||
| Uninvolved | 22 | 24 | 25 | 18 | 16 |
| MT ratio <0.33 | 63 | 65 | 59 | 63 | 74 |
| 0.33 ≤ MT ≤ 0.45 | 6 | 4 | 8 | 9 | 4 |
| MT >0.45 | 9 | 7 | 8 | 10 | 6 |
| Tumor >10 cm (%) | 24 | 25 | 28 | 22 | 26 |
| Inguinal involvement (%) | 19 | 13 | 19 | 22 | 26 |
| Extranodal sites ≥2 (%) | 27 | 21 | 22 | 25 | 23 |
| Bone marrow involvement (%) | 20 | 12 | 16 | 20 | 18 |
| ECOG performance status ≥2 (%) | 12 | 8 | 10 | 11 | 11 |
| Hemoglobin <10.5 g/L (%) | 29 | 24 | 34 | 21 | 22 |
| LDH ratio >1 (%) | 44 | 36 | 40 | 42 | 45 |
| Albumin <40 g/L (%) | 23 | 20 | 30 | 22 | 22 |
| WBC ≥15 × 109/L (%) | 25 | 21 | 25 | 19 | 27 |
| Lymphocyte count <0.6 × 109/L or <8% of WBC (%) | 13 | 8 | 16 | 12 | 8 |
| International prognostic score (%) | |||||
| 0 | 2 | 0 | 4 | 0 | 2 |
| 1 | 8 | 10 | 11 | 11 | 6 |
| 2 | 29 | 31 | 25 | 37 | 32 |
| 3 | 28 | 30 | 27 | 24 | 27 |
| 4 | 19 | 21 | 22 | 15 | 22 |
| ≥5 | 14 | 8 | 11 | 13 | 11 |
| . | Eligible patients . | Patients randomized for consolidation treatment . | |||
|---|---|---|---|---|---|
| MOPP/ABV × 8 . | ABVPP × 8 . | MOPP/ABV × 6 + RTx . | ABVPP × 6 + RTx . | ||
| No. of patients | 533 | 92 | 116 | 114 | 96 |
| Male gender (%) | 66 | 73 | 68 | 68 | 67 |
| Age | |||||
| Median (y) | 32 | 32 | 32 | 32 | 32 |
| ≥45 y (%) | 23 | 21 | 16 | 17 | 22 |
| Stage | |||||
| IIIB (%) | 40 | 52 | 41 | 39 | 46 |
| IVA (%) | 12 | 10 | 11 | 13 | 10 |
| IVB (%) | 48 | 38 | 48 | 48 | 44 |
| Mediastinum (%) | |||||
| Uninvolved | 22 | 24 | 25 | 18 | 16 |
| MT ratio <0.33 | 63 | 65 | 59 | 63 | 74 |
| 0.33 ≤ MT ≤ 0.45 | 6 | 4 | 8 | 9 | 4 |
| MT >0.45 | 9 | 7 | 8 | 10 | 6 |
| Tumor >10 cm (%) | 24 | 25 | 28 | 22 | 26 |
| Inguinal involvement (%) | 19 | 13 | 19 | 22 | 26 |
| Extranodal sites ≥2 (%) | 27 | 21 | 22 | 25 | 23 |
| Bone marrow involvement (%) | 20 | 12 | 16 | 20 | 18 |
| ECOG performance status ≥2 (%) | 12 | 8 | 10 | 11 | 11 |
| Hemoglobin <10.5 g/L (%) | 29 | 24 | 34 | 21 | 22 |
| LDH ratio >1 (%) | 44 | 36 | 40 | 42 | 45 |
| Albumin <40 g/L (%) | 23 | 20 | 30 | 22 | 22 |
| WBC ≥15 × 109/L (%) | 25 | 21 | 25 | 19 | 27 |
| Lymphocyte count <0.6 × 109/L or <8% of WBC (%) | 13 | 8 | 16 | 12 | 8 |
| International prognostic score (%) | |||||
| 0 | 2 | 0 | 4 | 0 | 2 |
| 1 | 8 | 10 | 11 | 11 | 6 |
| 2 | 29 | 31 | 25 | 37 | 32 |
| 3 | 28 | 30 | 27 | 24 | 27 |
| 4 | 19 | 21 | 22 | 15 | 22 |
| ≥5 | 14 | 8 | 11 | 13 | 11 |